|
Complaints Rising on Pharma Comparative Claim Violations
A sharp increase in exaggerated or misleading comparative claims in drug advertisements has the FDA analyzing the issue and considering guidance on it to help stop the violations.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives